Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:12 PM ET 8-K/A
M&A Deal Rank One Computing Corp ROC

Rank One Computing M&A Deal with Zuccaro Technical Consulting LLC

Rank One Computing Corporation (ROC) filed this amendment to provide required audited and pro forma financial statements following its completed acquisition of Zuccaro Technical Consulting LLC (ZTC). The transaction, which closed on August 31, 2026, involved ROC acquiring all issued and outstanding membership interests of ZTC from ZTC Holdco, Inc.

Counterparty
Zuccaro Technical Consulting LLC
4:11 PM ET 8-K
M&A Deal Fulcrum Therapeutics, Inc. FULC

Fulcrum Therapeutics Signs $7M M&A Deal with Slate Medicines, Inc.

Fulcrum Therapeutics entered into an agreement to sell its early-stage fetal hemoglobin (HbF) assets to an unaffiliated third-party pharmaceutical company for $7.0 million in cash. The sale is a strategic update to its pending merger with Slate Medicines, as the proceeds will be credited to Fulcrum's net cash and are expected to increase the cash dividend declared in connection with the merger.

Value
$7M
Counterparty
Slate Medicines, Inc.
4:11 PM ET 8-K
M&A Deal Lineage Cell Therapeutics, Inc. LCTX

Lineage Cell Therapeutics Signs $2.4M M&A Deal with NeuroAirmid Therapeutics, Inc.

Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics, Inc., adding a clinical-stage neural cell therapy program (HUNT1) for Huntington’s Disease to its pipeline. The deal involved a $2.4 million upfront cash payment and the assumption of a co-funding obligation for an ongoing Phase 1b/2a clinical study supported by CIRM.

Value
$2.4M
Counterparty
NeuroAirmid Therapeutics, Inc.

“Today, we closed the acquisition of NeuroAirmid Therapeutics adding HUNT1, a third clinical-stage asset to our development pipeline. HUNT1 is a pluripotent stem cell derived, clinical-stage neural cell therapy program, with the potential to validate a new cell-based treatment modality for Huntington’s Disease.”

Brian M. Culley, Lineage CEO

“This transaction reflects the disciplined approach to capital allocation and strategic fit that we believe our investors have come to expect from Lineage. HUNT1 was created on the same proprietary cell line that Lineage uses and is compatible with its AlloSCOPE “5D” technology, providing us with a head start on our planned contributions.”

Brian M. Culley, Lineage CEO
4:10 PM ET 8-K/A
Capital Raise Neuronetics, Inc. STIM

Neuronetics Capital Raise of $30M

Neuronetics, Inc. entered into an underwriting agreement to sell 18,750,000 shares of common stock at a public offering price of $1.60 per share. The company also granted underwriters a 30-day option to purchase an additional 2,812,500 shares, bringing the total potential gross proceeds to approximately $34.5 million. Net proceeds will be used to repay a portion of outstanding term loans under its Perceptive Credit Facility and for general corporate purposes.

Value
$30M
Counterparty
William Blair & Company, L.L.C.
4:09 PM ET 8-K
M&A Deal Launch Two Acquisition Corp. LPBB

Launch Two Acquisition M&A Deal with NuCube Energy, Inc.

Launch Two Acquisition Corp. (SPAC) has filed an updated investor presentation regarding its previously announced pending business combination with NuCube Energy, Inc. The presentation is intended for use in meetings with institutional investors and analysts to discuss the proposed merger and NuCube's microreactor technology for industrial and data center energy needs. The parties have already filed a Registration Statement on Form S-4 as they work toward closing the transaction.

Counterparty
NuCube Energy, Inc.
4:07 PM ET 8-K
Capacity Expansion Applied Optoelectronics, Inc. AAOI

Applied Optoelectronics Capacity Expansion: $102M Investment

Applied Optoelectronics completed the $102.25 million acquisition of three buildings at Hightower Business Park in Houston, Texas, totaling approximately 736,216 square feet. The company exercised purchase options in its existing leases to secure the facilities for manufacturing, warehouse, and office use, subsequently terminating the related lease agreements.

Value
$102M
Counterparty
Hightower Phase I Owner, LLC
4:06 PM ET 8-K
M&A Deal GoPro, Inc. GPRO

GoPro M&A Deal with Action Acquisition LLC

GoPro entered into an amendment to its existing merger agreement with Action Acquisition LLC, extending the deal's outside closing date from December 31, 2026, to March 31, 2027. The amendment also includes technical adjustments for potential stock splits or reclassifications and corrects a scrivener's error regarding the parent company's name. Parent is required to seek an extension of its financing commitment letter to match the new March 2027 deadline.

Counterparty
Action Acquisition LLC
3:44 PM ET 8-K
M&A Deal Integral Technologies Inc ITKG

Integral Technologies M&A Deal with Apex North LLC

Integral Technologies, Inc. completed the acquisition of an 80% membership interest in Apex North LLC, a mining company owning 394 unpatented lode claims in Utah. The transaction is structured as a reverse merger, causing the company to cease being a shell company and resulting in a change of control. Apex North's assets include the Apex North Critical Minerals Project covering approximately 8,141 acres of BLM-administered land.

Counterparty
Apex North LLC
1:57 PM ET 8-K
Capital Raise WF Card Funding LLC

WF Card Funding Capital Raise

WF Card Issuance Trust, an entity sponsored by Wells Fargo Bank, completed the issuance of its Class A(2026-2) Notes on November 12, 2026. In connection with the closing, the depositor reported a Transferor Interest of approximately $4.12 billion to satisfy U.S. credit risk retention requirements.

1:02 PM ET 8-K
Capital Raise Honda Auto Receivables 2026-4 Owner Trust

Honda Auto Receivables 2026-4 Owner Trust Capital Raise

Honda Auto Receivables 2026-4 Owner Trust completed the issuance and sale of Class A-1, A-2a, A-2b, A-3, and A-4 Asset Backed Notes. The transaction involved the transfer of retail installment sale contracts for Honda and Acura automobiles from American Honda Finance Corporation to the issuing entity through a series of definitive agreements including an Indenture and Sale and Servicing Agreement.

Counterparty
American Honda Finance Corporation
12:55 PM ET
Earnings Call Forgent Power Solutions, Inc. FPS ▶ Call

Forgent Power Solutions Earnings Call: Key Takeaways

Forgent Power Solutions delivered a significant Q1 beat and raised FY2027 guidance, emphasizing that data center demand remains resilient despite post-election regulatory uncertainty and supply constraints.

Call
Nov 12, 2026, 11:00 AM ET
12:46 PM ET
Earnings Call Forgent Power Solutions, Inc. FPS ▶ Call

Forgent Power Solutions Earnings Call: Key Takeaways

Forgent Power Solutions delivered a record-breaking fiscal 2026, significantly exceeding IPO forecasts and guidance while doubling manufacturing capacity and revenue to support surging AI-driven data center demand.

Call
Nov 12, 2026, 11:00 AM ET
12:45 PM ET 8-K
Divestiture Bluerock Homes Trust, Inc. BHM

Bluerock Homes Trust Divestiture for $6.6M

Bluerock Homes Trust completed the sale of 25 single-family residential units from its Golden Pacific portfolio to unaffiliated third parties for an aggregate price of approximately $6.6 million. This transaction is part of a larger disposition program that has seen the company sell a total of 86 units from the Indiana, Kansas, and Missouri portfolio throughout 2026. The company realized net proceeds of approximately $5.9 million from this specific tranche of sales after closing costs and adjustments.

Value
$6.6M
12:37 PM ET
Earnings Call Ondas Inc. ONDS ▶ Call

Ondas Earnings Call: Key Takeaways

Ondas is scaling rapidly through aggressive M&A and vertical integration, targeting $1.1 billion revenue in 2027 while pivoting toward sovereign AI and high-demand defense platforms.

Call
Nov 12, 2026, 8:30 AM ET
9:20 AM ET 8-K
M&A Deal Virtuix Holdings Inc. VTIX

Virtuix Holdings Signs $12M M&A Deal with STS International Inc.

Virtuix Holdings Inc. signed a non-binding letter of intent to acquire defense technology firm STS International for $12 million in cash and equity. The deal aims to establish a new 'Virtuix Defense' division, leveraging STS's $40 million in year-to-date revenue and established government contract vehicles. The transaction is expected to close by March 31, 2027, subject to definitive agreements and audited financial reviews.

Value
$12M
Counterparty
STS International Inc.
9:12 AM ET 8-K
Partnership Vishay Intertechnology Inc VSH

Vishay Intertechnology Partnership with Kaynes Technology India Limited Worth $56.4M

Vishay Intertechnology entered into a binding term sheet with Kaynes Technology India Limited to establish a semiconductor manufacturing joint venture in India. Vishay will invest $56.4 million for a 49% interest in the JV, which will focus on back-end manufacturing capabilities including wafer processing, assembly, and testing. The parties intend to apply for government support under the India Semiconductor Mission 2.0 program.

Value
$56.4M
Counterparty
Kaynes Technology India Limited
9:03 AM ET 8-K
Capital Raise Dare Bioscience, Inc. DARE

Dare Bioscience Capital Raise

Stockholders of Daré Bioscience approved the potential future issuance of common stock upon the exercise of outstanding warrants in accordance with Nasdaq listing rules. The approval was obtained at a special meeting held on November 10, 2026, ensuring compliance with dilution limits for a previously initiated capital raise.

9:03 AM ET 8-K
M&A Deal Nexgel, Inc. NXGL

Nexgel M&A Deal with Fountainhead LifeSciences

NEXGEL announced a strategic recapitalization and update on a potential merger with Fountainhead LifeSciences, including its affiliates Sequence LifeScience and NVISION Biomedical Technologies. As part of the plan, holders of $14.125 million in convertible notes (95% of outstanding principal) agreed to convert their debt into common stock at $5.50 per share, contingent upon the completion of the merger.

Counterparty
Fountainhead LifeSciences
8:51 AM ET 8-K
Capital Raise Boxlight Corp BOXL

Boxlight Capital Raise

Boxlight stockholders approved several proposals at a special meeting, including the issuance of shares exceeding 19.99% of outstanding stock related to Series D and Series E Preferred Stock financings and an equity line of credit. These approvals satisfy Nasdaq Listing Rule 5635(d) and are part of the company's plan to maintain compliance with Nasdaq's stockholders' equity requirements. The company expects to receive $2 million from the second tranche of its Series D financing and begin utilizing a $15 million equity line of credit.

Counterparty
Secure Net Capital LLC
8:42 AM ET 8-K
Clinical Trial Data MetaVia Inc. MTVA

MetaVia Clinical Trial Data

MetaVia announced additional positive data from Part 3B of its Phase 1 clinical trial of DA-1726, demonstrating a statistically significant 1.47 mg/dL placebo-adjusted reduction in serum uric acid after 16 weeks. These results complement previously reported data showing a 68.1% reduction in liver fat and 13.5% weight loss, supporting the drug's advancement into a Phase 2 study for MetALD and ALD planned for late 2027.

8:42 AM ET 8-K
M&A Deal Nano Mobile Healthcare, Inc. VNTH

Nano Mobile Healthcare M&A Deal with Neptune Engineering Limited

Nano Mobile Healthcare provided a status update on its pending acquisition of Neptune Engineering (Marine) Limited, which is now expected to close in the fourth quarter of 2026. The company filed unaudited pro forma condensed combined financial information reflecting the transaction, which involves issuing 20 million shares of common stock to acquire Neptune and raise cash from investors.

Counterparty
Neptune Engineering (Marine) Limited
8:38 AM ET 8-K
M&A Deal Investcorp Credit Management BDC, Inc. ICMB

Investcorp Credit Management BDC M&A Deal with BCP Investment Corporation

Investcorp Credit Management BDC (ICMB) has entered into a definitive agreement to be acquired by BCP Investment Corporation (BCIC). ICMB stockholders will receive aggregate consideration equal to 90% of ICMB’s net asset value at closing, paid primarily in BCIC shares (capped at 19.99% of BCIC's outstanding stock) with the remainder in cash.

Counterparty
BCP Investment Corporation

“This transaction marks another step in executing our vision of driving consolidation across the BDC sector. We have long believed that greater scale can deliver meaningful benefits, and the combination of ICMB and BCIC is expected to generate immediate cost synergies, lower financing costs and improved trading liquidity.”

Ted Goldthorpe, Chief Executive Officer and Chairman of the Board of BCIC

“This transaction reflects ICMB’s longstanding commitment to pursuing optimal returns for our stockholders. We believe the combination with BCIC positions the Company to deliver long-term value for stockholders. ICMB’s size and scale have been challenging to navigate in current market conditions.”

Suhail A. Shaikh, President and Chief Executive Officer of ICMB
8:38 AM ET 8-K
M&A Deal BCP Investment Corp BCIC

BCP Investment M&A Deal with Investcorp Credit Management BDC, Inc.

BCP Investment Corp (BCIC) has entered into a definitive agreement to acquire Investcorp Credit Management BDC, Inc. (ICMB) in a merger transaction. ICMB stockholders will receive consideration equal to 90% of ICMB's net asset value at closing, paid primarily in BCIC shares with a cash component if the share issuance exceeds a 19.99% cap. The deal is intended to drive sector consolidation and generate cost synergies through increased scale.

Counterparty
Investcorp Credit Management BDC, Inc.

“This transaction marks another step in executing our vision of driving consolidation across the BDC sector. We have long believed that greater scale can deliver meaningful benefits, and the combination of ICMB and BCIC is expected to generate immediate cost synergies, lower financing costs and improved trading liquidity. We believe these benefits will position the combined company to deliver stronger long-term value for stockholders.”

Ted Goldthorpe, Chief Executive Officer and Chairman of the Board of BCIC

“This transaction reflects ICMB’s longstanding commitment to pursuing optimal returns for our stockholders. We believe the combination with BCIC positions the Company to deliver long-term value for stockholders. ICMB’s size and scale have been challenging to navigate in current market conditions. We believe that a combination with BCIC provides our stockholders the benefits of scale and access that Sierra Crest brings in the private credit market.”

Suhail A. Shaikh, President and Chief Executive Officer of ICMB
8:35 AM ET 8-K
Divestiture Ellington Financial Inc. EFC

Ellington Financial Divestiture

Ellington Financial Inc. completed the sale of its mortgage servicing rights (MSR) related investments and excess servicing spread investments to an unaffiliated third party. The assets were originally acquired through the 2023 acquisition of Arlington Asset Investment Corp. and the sale is expected to free up more than $75 million in cash for redeployment into core strategies.

8:34 AM ET 8-K
Capital Raise Neuronetics, Inc. STIM

Neuronetics Capital Raise of $30M

Neuronetics, Inc. entered into an underwriting agreement to sell 18,750,000 shares of common stock at $1.60 per share, with an additional 2,812,500 shares available via an underwriters' option. The company expects to raise approximately $30 million in gross proceeds ($27.7 million net) to repay debt under its Perceptive Credit Facility and for general corporate purposes.

Value
$30M
Counterparty
William Blair & Company, L.L.C.
8:31 AM ET 8-K
M&A Deal M2i Global, Inc. MTWO

M2i Global Signs $100M M&A Deal with Happy Growth Group Limited

M2i Global entered into a definitive agreement to acquire 100% of Graphex Technologies LLC (GTL) from Happy Growth Group Limited for $100 million. The purchase price consists of $3 million in cash (via a note) and $97 million in common stock tranches tied to the delivery of a design and completion of a 50,000 metric ton per year graphite anode production plant in the U.S. The acquisition includes an exclusive license to 30 patents for natural graphite anode production across North America.

Value
$100M
Counterparty
Happy Growth Group Limited
8:31 AM ET 8-K
Partnership HeartCore Enterprises, Inc. HTCR

HeartCore Enterprises Partnership with ONE AI Co., Ltd.

HeartCore Enterprises entered into a non-exclusive business development and sales agency agreement with ONE AI Co., Ltd. to bring the Axis.ONE physical AI platform to industrial robots in Japan. The partnership aims to retrofit existing factory equipment with CPU-native, on-device AI capabilities for vision and decision-making without requiring GPU clusters or cloud dependency.

Counterparty
ONE AI Co., Ltd.
8:31 AM ET 8-K
Capital Raise GT Biopharma, Inc. GTBP

GT Biopharma Capital Raise

GT Biopharma shareholders approved a significant increase in authorized common shares from 25 million to 250 million and authorized the issuance of more than 19.99% of outstanding stock. These approvals facilitate the conversion of Series M Preferred Stock and the exercise of warrants related to a Securities Purchase Agreement dated September 14, 2026. The vote ensures compliance with Nasdaq Rule 5635 regarding the potential dilution from these previously announced financing transactions.

8:31 AM ET 8-K
M&A Deal VisionWave Holdings, Inc. VWAV

VisionWave Holdings Signs $7M M&A Deal with Europostachservice LLC

VisionWave Holdings entered into a non-binding Letter of Intent to acquire a 51% controlling interest in EPSERVICE, a Ukrainian developer of unmanned aerial systems and 'mothership' drone control technology. The proposed acquisition from Metal Machinery Components Trading – FZCO involves $7 million in cash consideration payable 90 days after closing. The deal is subject to technical due diligence in Ukraine, including a live flight demonstration of the ICMM system.

Value
$7M
Counterparty
EUROPOSTACHSERVICE LLC
8:30 AM ET 8-K
Clinical Trial Data Vivani Medical, Inc. VANI

Vivani Medical Clinical Trial Data

Vivani Medical announced positive top-line results from its SLIM-1 Phase 1 trial evaluating NPM-139, a miniature semaglutide implant for chronic weight management. The trial demonstrated that NPM-139 was well-tolerated with no treatment-related adverse events and achieved weight loss of 0.79% over four weeks, comparable to the 0.82% observed in the Wegovy control group.

Term
4 weeks

“The third quarter and recent weeks mark a period of strong progress and forward momentum for Vivani. The top-line SLIM-1 results will be announced this week. We look forward to sharing those results with shareholders, industry peers, and the broader community of physicians and patients seeking less frequent dosing and the promise of potential improvements in convenience, medication adherence, and tolerability associated with GLP-1 therapies on the market and in clinical-stage development.”

Adam Mendelsohn, PhD, CEO

“Roughly half of patients don’t take their medications for chronic diseases as prescribed, and GLP-1 therapies are no exception. With NPM-139, we are designing a novel GLP-1 therapy that a patient could receive once or twice a year during a routine primary care visit.”

Adam Mendelsohn, PhD, CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.